Featured Press Releases

Bavarian Nordic gets a HERA order and announces a major vaccine donation for the Mpox outbreak in Africa

Bavarian Nordic gets a HERA order and announces a major vaccine donation for the Mpox outbreak in Africa

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

  • 21 Aug 2024

ImmPACT Bio USA Inc.a clinical-stage biopharmaceutical company developing a new generation of...

Repare Therapeutics announces promising Phase 1 data showing the effectiveness of Camonsertib in combination with radiotherapy treatment

Repare Therapeutics announces promising Phase 1 data showing the effectiveness of Camonsertib in combination with radiotherapy treatment

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

PeptiGrowth Inc. Launches Novel Synthetic KGF Alternative Peptide (FGFR2b Agonist)

PeptiGrowth Inc. Launches Novel Synthetic KGF Alternative Peptide (FGFR2b Agonist)

Glenmark Pharmaceuticals Launches Vancomycin Hydrochloride for Injection in the U.S

Glenmark Pharmaceuticals Launches Vancomycin Hydrochloride for Injection in the U.S

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

  • Cellenkos, Inc.
  • 27 Apr 2026
Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

  • Ascletis Pharma Inc.
  • 27 Apr 2026
OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

  • OrthoTrophix, Inc.
  • 26 Apr 2026
Bristol Myers Squibb and Pfizer to provide Eliquis® (apixaban) through the Mark Cuban Cost Plus Drug Company

Bristol Myers Squibb and Pfizer to provide Eliquis® (apixaban) through the Mark Cuban Cost Plus Drug Company

  • Bristol Myers Squibb
  • 24 Apr 2026
CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

  • Neurocrine Biosciences, Inc.
  • 22 Apr 2026
Merck’s once-daily IDVYNSO™ (doravirine/islatravir) receives FDA approval

Merck’s once-daily IDVYNSO™ (doravirine/islatravir) receives FDA approval

  • Merck & Co., Inc.
  • 21 Apr 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.